These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 25588857)
1. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer. McNamara KM; Yoda T; Miki Y; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Nishimura R; Arima N; Tamaki K; Ishida T; Ohuchi N; Sasano H Int J Biol Markers; 2015 May; 30(2):e184-9. PubMed ID: 25588857 [TBL] [Abstract][Full Text] [Related]
2. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Choi JE; Kang SH; Lee SJ; Bae YK Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503 [TBL] [Abstract][Full Text] [Related]
4. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression. Abd-Elazeem MA; Abd-Elazeem MA Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318 [TBL] [Abstract][Full Text] [Related]
5. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. McNamara KM; Yoda T; Nurani AM; Shibahara Y; Miki Y; Wang L; Nakamura Y; Suzuki K; Yang Y; Abe E; Hirakawa H; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Brown KA; Ohuchi N; Sasano H Breast Cancer Res Treat; 2014 Jun; 145(2):281-93. PubMed ID: 24715382 [TBL] [Abstract][Full Text] [Related]
6. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers. Zuo T; Wilson P; Cicek AF; Harigopal M Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor status is highly conserved during tumor progression of breast cancer. Grogg A; Trippel M; Pfaltz K; Lädrach C; Droeser RA; Cihoric N; Salhia B; Zweifel M; Tapia C BMC Cancer; 2015 Nov; 15():872. PubMed ID: 26552477 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response. Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539 [TBL] [Abstract][Full Text] [Related]
9. Association between androgen receptor status and prognosis in triple negative breast cancer. Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854 [TBL] [Abstract][Full Text] [Related]
10. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis. Wang C; Pan B; Zhu H; Zhou Y; Mao F; Lin Y; Xu Q; Sun Q Oncotarget; 2016 Jul; 7(29):46482-46491. PubMed ID: 27374089 [TBL] [Abstract][Full Text] [Related]
12. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Shibahara Y; Miki Y; Sakurada C; Uchida K; Hata S; McNamara K; Yoda T; Takagi K; Nakamura Y; Suzuki T; Ishida T; Ohuchi N; Sasano H Hum Pathol; 2013 Oct; 44(10):2338-45. PubMed ID: 23953348 [TBL] [Abstract][Full Text] [Related]
14. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Tsutsumi Y Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930 [TBL] [Abstract][Full Text] [Related]
15. Characteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer. Goto Y; Thike AA; Ong CCH; Lim JX; Md Nasir ND; Li H; Koh VCY; Chen XY; Yeong JPS; Sasano H; Tan PH J Clin Pathol; 2020 Mar; 73(3):147-153. PubMed ID: 31563883 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308 [TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer. Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597 [TBL] [Abstract][Full Text] [Related]
18. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers. Safarpour D; Tavassoli FA Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144 [TBL] [Abstract][Full Text] [Related]
19. Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer. Thakkar A; Wang B; Picon-Ruiz M; Buchwald P; Ince TA Breast Cancer Res Treat; 2016 May; 157(1):77-90. PubMed ID: 27120467 [TBL] [Abstract][Full Text] [Related]
20. Imaging features of triple-negative breast cancers according to androgen receptor status. Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]